FKBP12 PROTAC dTAG-13 - 10mM in DMSO, high purity , CAS No.2064175-41-1(DMSO)

Item Number

F655331

• Specifications & Purity: 10mM in DMSO
• Storage Temp: Store at -80°C
• Shipped In: Ice chest + Ice pads

Product Description

FKBP12 PROTAC dTAG-13 (dTAG-13), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 effectively engages FKBP12 F36V and CRBN, thereby selectively degrading FKBP12 F36V

In Vitro

TAG-13 (1-1000 nM; 4 hours; 293FT WT cells) treatment potently reduces FKBP12 F36V -Nluc levels in 293FT WT cell, indicating the requirement of CRBN for the observed effects. Treatment of MV4;11 cells expressing BRD4(short)-FKBP12 F36V with dTAG-13 leads to robust degradation of BRD4. dTAG-13 treatment leads to rapid degradation of BRD4 within one hou. dTAG-13 treatment leads to rapid and potent degradation of the BRD4 fusion chimera in the heterozygous and homozygous knock-in clones, with no effect on endogenous FKBP12 WT. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: 293FT WT cells Concentration: 1 nM, 10 nM, 100 nM, 1000 nM Incubation Time: 4 hours Result: Potently reduced FKBP12 F36V -Nluc levels in 293FT WT cell.

In Vivo

Following bone marrow engraftment of MV4;11 cells expressing luc-FKBP12F36V in mice, the bioluminescent signal after vehicle or dTAG-13 administration is monitored. A significant, rapid, and durable effect on bioluminescent signal is observed four hours after dTAG-13 administration, indicating effective degradation of luc-FKBP12F36V. Twenty-eight hours following the final treatment, the recovery of cellular bioluminescence to levels comparable between vehicle and dTAG-13 treatment groups is observed . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:Cereblon FKBP12(F36V)